Rafael Holdings, Inc.RFL

時価総額

PER

臨床・前臨床の医薬品企業への投資持株会社の有力企業。希少疾患向け治療候補やリポソーム医薬などパイプラインを展開。2024年1月の子会社買収、2024年3月の主要持分再編、2024年8月21日の臨床会社との合併協定。米国、イスラエル、欧州を中心に展開。

概要財務

サマリーテーブルに戻る

	2018年 7月31日	2019年 7月31日	2020年 7月31日	2021年 7月31日	2022年 7月31日	2023年 7月31日	2024年 7月31日
Infusion Technology	-	-	-	-	-	-	0
Rental – Third Party	-	-	-	-	-	0	0
Rental – Related Party	-	-	-	-	-	0	0
Total revenue	4	5	5	4	0	0	1
Cost of Infusion Technology revenue	-	-	-	-	-	-	0
General and administrative	-	-	-	-	-	9	9
Research and development	1	1	2	5	9	6	4
In-process research and development expense	-	-	-	-	-	-	90
Depreciation and amortization	2	2	2	1	0	0	0
Loss from operations	-4	-7	-8	-30	-60	-15	-103
Interest income	-	-	-	-	0	3	2
Impairment of investments - Other Pharmaceuticals	-	-	-	-	79	-	-
Loss on initial investment in Day Three upon acquisition	-	-	-	-	-	-	2
Realized gain on available-for-sale securities	-	-	-	-	-	-	2
Realized gain (loss) on investment in equity securities	-	-	-	-	-	0	-0
Unrealized gain on investment in equity securities	-	-	-	-	-	0	-
Realized gain on investment - Cyclo	-	-	-	-	-	-	0
Unrealized gain on investment - Cyclo	-	-	-	-	-	-	0
Unrealized gain on convertible notes receivable, due from Cyclo	-	-	-	-	-	-	1
Unrealized gain on investment - Hedge Funds	-	-	-	-	-	-	0
Recovery of receivables from Cornerstone	-	-	-	-	-	-	31
Interest expense	-	-	-	-	0	-	0
Other income	-	-	-	-	-	-	0
Loss from continuing operations before income taxes	-4	-5	-7	-25	-140	-9	-67
Benefit from income taxes	8	-0	0	0	-	-0	-3
Equity in loss of Day Three	-	-	-	-	-	-	0
Consolidated net loss from continuing operations	-	-	-	-	-141	-9	-65
Loss from discontinued operations related to 520 Property	-	-	-	-	-	-0	-
Gain on disposal of 520 Property	-	-	-	-	-2	7	-
Income from discontinued operations	-	-	-	-	-2	6	-
Consolidated net loss	-12	-5	-11	-	-142	-2	-65
Net loss attributable to noncontrolling interests	-0	-0	-0	-	-18	-0	-31
Net loss attributable to Rafael Holdings, Inc.	-12	-5	-10	-25	-141	-2	-34
Consolidated net loss	-12	-5	-11	-	-142	-2	-65
Unrealized (loss) gain on available-for-sale securities	-	-	-	-	-	-0	0
Foreign currency translation adjustment	-	-	-	-	0	-	0
Comprehensive loss	-	-5	-11	-	-	-3	-65
Comprehensive loss attributable to noncontrolling interests	-	-	-	-	-	-	-31
Comprehensive loss attributable to Rafael Holdings, Inc.	-	-4	-11	-25	-125	-2	-34
Continuing operations basic (in Dollars per share)	-	-	-	-	-6.22	-0.36	-1.45
Continuing operations diluted (in Dollars per share)	-	-	-	-	-	-	-1.45
Discontinued operations basic (in Dollars per share)	-	-	-	-	-0.09	0.28	-
Total basic loss per share (in Dollars per share)	-0.93	-	-	-	-6.31	-0.08	-1.45
Total diluted loss per share (in Dollars per share)	-0.93	-	-	-	-6.31	-0.08	-1.45